Heart failure & cardiomyopathiesCohort study
Timing of Sodium–Glucose Cotransporter 2 Inhibitor Initiation and Post-Discharge Outcomes in Acute Heart Failure with Diabetes: A Population-Based Cohort Study
- Retrospective cohort study
- population-based
- target trial emulation
- clone-censor-weight approach
Authors' conclusion
Real-world evidence supports early SGLT2 inhibitor initiation to reduce HHF or cardiovascular mortality in acute heart failure and type 2 diabetes.
Study context
- Population
- Adults aged ≥66 years with T2DM discharged to the community after acute HF hospitalization, Ontario, Canada, 2016–202038,564 clones
- Participants
- 9,641 adults
- Exposure
- Early vs delayed post-discharge SGLT2 inhibitor initiation
- Outcome
- Composite of:
- Hospitalization for heart failure (HHF)
- CV mortality
- Follow-up
- 1 year
Main finding
As reported in the abstract
Each group vs delayedRelative risk (95% CI)
Within 3 days
0.65(0.45–0.83)
4-90 days
0.83(0.72–0.93)
91-180 days
0.89(0.79–0.97)
Observational data: associations, not effects.
Original publication
Timing of Sodium–Glucose Cotransporter 2 Inhibitor Initiation and Post-Discharge Outcomes in Acute Heart Failure with Diabetes: A Population-Based Cohort Study. Eur J Heart Fail. Published 12 September 2024. doi:10.1002/ejhf.3464
Summarised from the published abstract; every number is checked against it